Tema Etfs LLC Buys Shares of 5,385 Insulet Co. (NASDAQ:PODD)

Tema Etfs LLC bought a new position in Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,385 shares of the medical instruments supplier's stock, valued at approximately $1,406,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PODD. Horizon Investments LLC raised its stake in shares of Insulet by 3.1% in the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock worth $362,000 after acquiring an additional 42 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock worth $1,146,000 after purchasing an additional 43 shares during the last quarter. Wilmington Savings Fund Society FSB lifted its holdings in Insulet by 9.6% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier's stock worth $140,000 after buying an additional 47 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Insulet by 2.3% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock valued at $552,000 after buying an additional 48 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in Insulet by 5.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock worth $274,000 after purchasing an additional 50 shares during the period.

Insider Buying and Selling at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the transaction, the senior vice president now owns 23,180 shares in the company, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Analysts Set New Price Targets

Several brokerages have commented on PODD. StockNews.com cut shares of Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Oppenheimer upped their target price on shares of Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective on the stock in a report on Tuesday, May 13th. Piper Sandler increased their price target on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Finally, Raymond James restated an "outperform" rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $306.53.

Insulet Price Performance

NASDAQ PODD traded down $2.97 during midday trading on Wednesday, hitting $324.50. The company had a trading volume of 653,394 shares, compared to its average volume of 707,724. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a twelve month low of $170.67 and a twelve month high of $329.50. The company has a market capitalization of $22.84 billion, a PE ratio of 56.05, a P/E/G ratio of 3.62 and a beta of 1.26. The firm has a 50-day moving average price of $267.35 and a 200-day moving average price of $267.99.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. During the same period in the prior year, the business earned $0.73 earnings per share. The company's revenue for the quarter was up 28.8% compared to the same quarter last year. As a group, analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.